Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 5/2022

01-05-2022 | Metastasis | Review Article

Cancer-associated fibroblasts in colorectal cancer

Authors: S. Kamali Zonouzi, P. S. Pezeshki, S. Razi, N. Rezaei

Published in: Clinical and Translational Oncology | Issue 5/2022

Login to get access

Abstract

Colorectal cancer (CRC) is one of the leading causes of mortality among cancers. Many aspects of this cancer are under investigation to find established markers of diagnosis, prognosis, and also potential drug targets. In this review article, we are going to discuss the possible solution to all these aims by investigating the literature about cancer-associated fibroblasts (CAFs) involved in CRC. Moreover, we are going to review their interaction with the tumor microenvironment (TME) and vitamin D and their role in tumorigenesis and metastasis. Moreover, we are going to expand more on some markers produced by them or related to them including FAP, a-SMA, CXCL12, TGF- β, POSTN, and β1-Integrin. Some signaling pathways related to CAFs are as follows: FAK, AKT, activin A, and YAP/TAZ. Some genes related to the CAFs which are found to be possible therapeutic targets include COL3A1, JAM3, AEBP1 and, CAF-derived TGFB3, WNT2, and WNT54.
Literature
1.
2.
Cheng L, et al. Trends in colorectal cancer incidence by anatomic site and disease stage in the United States from 1976 to 2005. Am J Clin Oncol. 2011;34(6):573–80.PubMedCrossRef
3.
Raftery L, Goldberg RM. Optimal delivery of cytotoxic chemotherapy for colon cancer. Cancer J. 2010;16(3):214–9.PubMedCrossRef
4.
Vodenkova S, et al. 5-fluorouracil and other fluoropyrimidines in colorectal cancer: past, present and future. Pharmacol Ther. 2020;206:107447.PubMedCrossRef
5.
Nissen NI, et al. Prognostic value of blood-based fibrosis biomarkers in patients with metastatic colorectal cancer receiving chemotherapy and bevacizumab. Sci Rep. 2021;11(1):865.PubMedPubMedCentralCrossRef
6.
Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell. 2012;21(3):309–22.PubMedCrossRef
7.
Quante M, et al. Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell. 2011;19(2):257–72.PubMedPubMedCentralCrossRef
8.
9.
Wu X, et al. Repurposing vitamin D for treatment of human malignancies via targeting tumor microenvironment. Acta Pharm Sin B. 2019;9(2):203–19.PubMedCrossRef
10.
Fujita M, et al. Peptide TNIIIA2 derived from Tenascin-C contributes to malignant progression in colitis-associated colorectal cancer via β1-Integrin activation in fibroblasts. Int J Mol Sci. 2019;20(11):2752.PubMedCentralCrossRef
11.
Kasashima H, et al. Stromal SOX2 upregulation promotes tumorigenesis through the generation of a SFRP1/2-expressing cancer-associated fibroblast population. Dev Cell. 2021;56(1):95-110.e10.PubMedCrossRef
12.
Herrera A, et al. Endothelial cell activation on 3D-matrices derived from PDGF-BB-stimulated fibroblasts is mediated by Snail1. Oncogenesis. 2018;7(9):76.PubMedPubMedCentralCrossRef
13.
Huang, T.X., et al. Targeting cancer-associated fibroblast-secreted WNT2 restores dendritic cell-mediated antitumour immunity. Gut 2021:322924.
14.
Unterleuthner D, et al. Cancer-associated fibroblast-derived WNT2 increases tumor angiogenesis in colon cancer. Angiogenesis. 2020;23(2):159–77.PubMedCrossRef
15.
Coto-Llerena M, et al. High expression of FAP in colorectal cancer is associated with angiogenesis and immunoregulation processes. Front Oncol. 2020;10:979.PubMedPubMedCentralCrossRef
16.
Nishishita R, et al. Expression of cancer-associated fibroblast markers in advanced colorectal cancer. Oncol Lett. 2018;15(5):6195–202.PubMedPubMedCentral
17.
Solano-Iturri JD, et al. Altered expression of fibroblast activation protein-α (FAP) in colorectal adenoma-carcinoma sequence and in lymph node and liver metastases. Aging (Albany NY). 2020;12(11):10337–58.CrossRef
18.
Chen L, et al. FAP positive fibroblasts induce immune checkpoint blockade resistance in colorectal cancer via promoting immunosuppression. Biochem Biophys Res Commun. 2017;487(1):8–14.PubMedCrossRef
19.
Wanandi SI, et al. Cancer-associated fibroblast (CAF) secretomes-induced epithelial-mesenchymal transition on HT-29 colorectal carcinoma cells associated with hepatocyte growth factor (HGF) signalling. J Pak Med Assoc. 2021;71(2):S18–24 (Suppl 2).PubMed
20.
Herrera M, et al. Cancer-associated fibroblast and M2 macrophage markers together predict outcome in colorectal cancer patients. Cancer Sci. 2013;104(4):437–44.PubMedPubMedCentralCrossRef
21.
22.
Mochizuki S, et al. Expression and function of a disintegrin and metalloproteinases in cancer-associated fibroblasts of colorectal cancer. Digestion. 2020;101(1):18–24.PubMedCrossRef
23.
Yang T, et al. Increased RAB31 expression in cancer-associated fibroblasts promotes colon cancer progression through HGF-MET signaling. Front Oncol. 2020;10:1747.PubMedPubMedCentralCrossRef
24.
Gu C, Lu H, Qian Z. Matrine reduces the secretion of exosomal circSLC7A6 from cancer-associated fibroblast to inhibit tumorigenesis of colorectal cancer by regulating CXCR5. Biochem Biophys Res Commun. 2020;527(3):638–45.PubMedCrossRef
25.
Ma H, et al. Periostin promotes colorectal tumorigenesis through integrin-FAK-Src pathway-mediated YAP/TAZ activation. Cell Rep. 2020;30(3):793-806.e6.PubMedCrossRef
26.
Thongchot S, et al. Periostin regulates autophagy through integrin α5β1 or α6β4 and an AKT-dependent pathway in colorectal cancer cell migration. J Cell Mol Med. 2020;24(21):12421–32.PubMedPubMedCentralCrossRef
27.
Chen, W., et al. CaMKII mediates TGFβ1-induced fibroblasts activation and its cross talk with colon cancer cells. Dig Dis Sci. 2021.
28.
Tanabe Y, et al. Blockade of the chemokine receptor, CCR5, reduces the growth of orthotopically injected colon cancer cells via limiting cancer-associated fibroblast accumulation. Oncotarget. 2016;7(30):48335–45.PubMedPubMedCentralCrossRef
29.
Stadler S, et al. Colon cancer cell-derived 12(S)-HETE induces the retraction of cancer-associated fibroblast via MLC2, RHO/ROCK and Ca(2+) signalling. Cell Mol Life Sci. 2017;74(10):1907–21.PubMedCrossRef
30.
Herrera M, et al. Differential distribution and enrichment of non-coding RNAs in exosomes from normal and cancer-associated fibroblasts in colorectal cancer. Mol Cancer. 2018;17(1):114.PubMedPubMedCentralCrossRef
31.
Bhome R, et al. Exosomal microRNAs derived from colorectal cancer-associated fibroblasts: role in driving cancer progression. Aging (Albany NY). 2017;9(12):2666–94.CrossRef
32.
Fourniols T, et al. Inhibition of colorectal cancer-associated fibroblasts by lipid nanocapsules loaded with acriflavine or paclitaxel. Int J Pharm. 2020;584:119337.PubMedCrossRef
33.
Wawro ME, et al. Nonsteroidal anti-inflammatory drugs prevent vincristine-dependent cancer-associated fibroblasts formation. Int J Mol Sci. 2019;20(8):1941.PubMedCentralCrossRef
34.
Yadav VK, et al. Preclinical evaluation of the novel small-molecule MSI-N1014 for treating drug-resistant colon cancer via the LGR5/β-catenin/miR-142-3p network and reducing cancer-associated fibroblast transformation. Cancers (Basel). 2020;12(6):1590.PubMedCentralCrossRef
35.
36.
37.
Bauer J, et al. Increased stiffness of the tumor microenvironment in colon cancer stimulates cancer associated fibroblast-mediated prometastatic activin A signaling. Sci Rep. 2020;10(1):50.PubMedPubMedCentralCrossRef
38.
39.
40.
Kawano S, et al. Assessment of elasticity of colorectal cancer tissue, clinical utility, pathological and phenotypical relevance. Cancer Sci. 2015;106(9):1232–9.PubMedPubMedCentralCrossRef
41.
42.
43.
Olsen AL, et al. Hepatic stellate cells require a stiff environment for myofibroblastic differentiation. Am J Physiol Gastrointest Liver Physiol. 2011;301(1):G110–8.PubMedPubMedCentralCrossRef
44.
Perepelyuk M, et al. Hepatic stellate cells and portal fibroblasts are the major cellular sources of collagens and lysyl oxidases in normal liver and early after injury. Am J Physiol Gastrointest Liver Physiol. 2013;304(6):G605–14.PubMedPubMedCentralCrossRef
45.
Bissell MJ, Hines WC. Why don’t we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med. 2011;17(3):320–9.PubMedPubMedCentralCrossRef
46.
Shibahara K, et al. Production of gastrointestinal tumors in mice by modulating latent TGF-β1 activation. Cancer Res. 2013;73(1):459–68.PubMedCrossRef
47.
Zhou W, et al. Oxidative stress induced autophagy in cancer associated fibroblast enhances proliferation and metabolism of colorectal cancer cells. Cell Cycle. 2017;16(1):73–81.PubMedCrossRef
48.
Peng S, et al. Enhancing cancer-associated fibroblast fatty acid catabolism within a metabolically challenging tumor microenvironment drives colon cancer peritoneal metastasis. Mol Oncol. 2021;15:1391.PubMedPubMedCentralCrossRef
49.
Abdul-Wahid A, et al. Serum-derived carcinoembryonic antigen (CEA) activates fibroblasts to induce a local re-modeling of the extracellular matrix that favors the engraftment of CEA-expressing tumor cells. Int J Cancer. 2018;143(8):1963–77.PubMedPubMedCentralCrossRef
50.
51.
Ferrer-Mayorga G, et al. Vitamin D receptor expression and associated gene signature in tumour stromal fibroblasts predict clinical outcome in colorectal cancer. Gut. 2017;66(8):1449–62.PubMedCrossRef
52.
Demuytere J, et al. The role of the peritoneal microenvironment in the pathogenesis of colorectal peritoneal carcinomatosis. Exp Mol Pathol. 2020;115:104442.PubMedCrossRef
53.
González-González L, Alonso J. Periostin: a matricellular protein with multiple functions in cancer development and progression. Front Oncol. 2018;8:225.PubMedPubMedCentralCrossRef
54.
55.
Hardwick JC, et al. Bone morphogenetic protein 2 is expressed by, and acts upon, mature epithelial cells in the colon. Gastroenterology. 2004;126(1):111–21.PubMedCrossRef
56.
Beck SE, et al. BMP-induced growth suppression in colon cancer cells is mediated by p21WAF1 stabilization and modulated by RAS/ERK. Cell Signal. 2007;19(7):1465–72.PubMedPubMedCentralCrossRef
57.
Beck SE, et al. Bone morphogenetic protein signaling and growth suppression in colon cancer. Am J Physiol Gastrointest Liver Physiol. 2006;291(1):G135–45.PubMedCrossRef
58.
Flier SN, et al. Identification of epithelial to mesenchymal transition as a novel source of fibroblasts in intestinal fibrosis. J Biol Chem. 2010;285(26):20202–12.PubMedPubMedCentralCrossRef
59.
Wu WK, et al. Bone morphogenetic protein signalling is required for the anti-mitogenic effect of the proteasome inhibitor MG-132 on colon cancer cells. Br J Pharmacol. 2008;154(3):632–8.PubMedPubMedCentralCrossRef
60.
Zeisberg M, Shah AA, Kalluri R. Bone morphogenic protein-7 induces mesenchymal to epithelial transition in adult renal fibroblasts and facilitates regeneration of injured kidney. J Biol Chem. 2005;280(9):8094–100.PubMedCrossRef
61.
Kosinski C, et al. Gene expression patterns of human colon tops and basal crypts and BMP antagonists as intestinal stem cell niche factors. Proc Natl Acad Sci USA. 2007;104(39):15418–23.PubMedPubMedCentralCrossRef
62.
Namkoong H, et al. The bone morphogenetic protein antagonist gremlin 1 is overexpressed in human cancers and interacts with YWHAH protein. BMC Cancer. 2006;6:74.PubMedPubMedCentralCrossRef
63.
Karagiannis GS, et al. Enrichment map profiling of the cancer invasion front suggests regulation of colorectal cancer progression by the bone morphogenetic protein antagonist, gremlin-1. Mol Oncol. 2013;7(4):826–39.PubMedPubMedCentralCrossRef
64.
Lugli A, et al. Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016. Mod Pathol. 2017;30(9):1299–311.PubMedCrossRef
65.
Mitrovic B, et al. Tumor budding in colorectal carcinoma: time to take notice. Mod Pathol. 2012;25(10):1315–25.PubMedCrossRef
66.
Sugai T, et al. Microenvironmental markers are correlated with lymph node metastasis in invasive submucosal colorectal cancer. Histopathology. 2021;79:584.PubMedPubMedCentralCrossRef
67.
Lee HO, et al. FAP-overexpressing fibroblasts produce an extracellular matrix that enhances invasive velocity and directionality of pancreatic cancer cells. BMC Cancer. 2011;11:245.PubMedPubMedCentralCrossRef
68.
Kelly T, et al. Fibroblast activation protein-α: a key modulator of the microenvironment in multiple pathologies. Int Rev Cell Mol Biol. 2012;297:83–116.PubMedCrossRef
69.
Liu R, et al. Fibroblast activation protein: a potential therapeutic target in cancer. Cancer Biol Ther. 2012;13(3):123–9.PubMedCrossRef
70.
Kramer N, et al. Autocrine WNT2 signaling in fibroblasts promotes colorectal cancer progression. Oncogene. 2017;36(39):5460–72.PubMedCrossRef
71.
Li J, et al. Carcinoma-associated fibroblasts lead the invasion of salivary gland adenoid cystic carcinoma cells by creating an invasive track. PLoS One. 2016;11(3):e0150247.PubMedPubMedCentralCrossRef
72.
Gaggioli C, et al. Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells. Nat Cell Biol. 2007;9(12):1392–400.PubMedCrossRef
73.
74.
Chen SX, et al. Identification of colonic fibroblast secretomes reveals secretory factors regulating colon cancer cell proliferation. J Proteomics. 2014;110:155–71.PubMedCrossRef
75.
Owusu BY, et al. Hepatocyte growth factor, a key tumor-promoting factor in the tumor microenvironment. Cancers (Basel). 2017;9(4):35.CrossRef
76.
Satoh K, et al. Tumor budding in colorectal carcinoma assessed by cytokeratin immunostaining and budding areas: possible involvement of c-Met. Cancer Sci. 2014;105(11):1487–95.PubMedPubMedCentralCrossRef
77.
Shangguan C, et al. Cancer-associated fibroblasts enhance tumor (18)F-FDG uptake and contribute to the intratumor heterogeneity of PET-CT. Theranostics. 2018;8(5):1376–88.PubMedPubMedCentralCrossRef
78.
Chang AL, et al. CCL2 Produced by the glioma microenvironment is essential for the recruitment of regulatory T Cells and myeloid-derived suppressor cells. Cancer Res. 2016;76(19):5671–82.PubMedPubMedCentralCrossRef
79.
Yang X, et al. FAP promotes immunosuppression by cancer-associated fibroblasts in the tumor microenvironment via STAT3-CCL2 signaling. Cancer Res. 2016;76(14):4124–35.PubMedCrossRef
80.
Hortobagyi, G.N., Edge S.B., Giuliano A. New and important changes in the TNM staging system for breast cancer. Am Soc Clin Oncol Educ Book. 2018;38:457–67.PubMedCrossRef
81.
Yan W, Shao R. Transduction of a mesenchyme-specific gene periostin into 293T cells induces cell invasive activity through epithelial-mesenchymal transformation. J Biol Chem. 2006;281(28):19700–8.PubMedCrossRef
82.
Xu X, et al. Periostin expression in intra-tumoral stromal cells is prognostic and predictive for colorectal carcinoma via creating a cancer-supportive niche. Oncotarget. 2016;7(1):798–813.PubMedCrossRef
83.
Zheng X, et al. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature. 2015;527(7579):525–30.PubMedPubMedCentralCrossRef
84.
Sugai T, et al. Analysis of the expression of cancer-associated fibroblast- and EMT-related proteins in submucosal invasive colorectal cancer. J Cancer. 2018;9(15):2702–12.PubMedPubMedCentralCrossRef
85.
Choi SY, et al. Podoplanin, α-smooth muscle actin or S100A4 expressing cancer-associated fibroblasts are associated with different prognosis in colorectal cancers. J Korean Med Sci. 2013;28(9):1293–301.PubMedPubMedCentralCrossRef
86.
87.
Horman SR, et al. Functional profiling of microtumors to identify cancer associated fibroblast-derived drug targets. Oncotarget. 2017;8(59):99913–30.PubMedPubMedCentralCrossRef
88.
Zanotti S, et al. Opposing roles of miR-21 and miR-29 in the progression of fibrosis in Duchenne muscular dystrophy. Biochim Biophys Acta. 2015;1852(7):1451–64.PubMedCrossRef
89.
90.
Layne MD, et al. Impaired abdominal wall development and deficient wound healing in mice lacking aortic carboxypeptidase-like protein. Mol Cell Biol. 2001;21(15):5256–61.PubMedPubMedCentralCrossRef
91.
Tumelty KE, et al. Aortic carboxypeptidase-like protein (ACLP) enhances lung myofibroblast differentiation through transforming growth factor β receptor-dependent and -independent pathways. J Biol Chem. 2014;289(5):2526–36.PubMedCrossRef
92.
Gonçalves-Ribeiro S, et al. Carcinoma-associated fibroblasts affect sensitivity to oxaliplatin and 5FU in colorectal cancer cells. Oncotarget. 2016;7(37):59766–80.PubMedPubMedCentralCrossRef
93.
Hanley CJ, et al. Targeting the myofibroblastic cancer-associated fibroblast phenotype through inhibition of NOX4. J Natl Cancer Inst. 2018;110(1):109–20.CrossRef
94.
95.
Fearon DT. The carcinoma-associated fibroblast expressing fibroblast activation protein and escape from immune surveillance. Cancer Immunol Res. 2014;2(3):187–93.PubMedCrossRef
96.
97.
Zadka Ł, et al. Interplay of stromal tumor-infiltrating lymphocytes, normal colonic mucosa, cancer-associated fibroblasts, clinicopathological data and the immunoregulatory molecules of patients diagnosed with colorectal cancer. Cancer Immunol Immunother. 2021;70(9):2681–700.PubMedPubMedCentralCrossRef
98.
99.
Kato T, et al. Cancer-associated fibroblasts affect intratumoral CD8(+) and FoxP3(+) T cells via IL6 in the tumor microenvironment. Clin Cancer Res. 2018;24(19):4820–33.PubMedCrossRef
100.
Patsalias A, Kozovska Z. Personalized medicine: stem cells in colorectal cancer treatment. Biomed Pharmacother. 2021;141:111821.PubMedCrossRef
101.
Xu H, et al. Cholesterol metabolism: new functions and therapeutic approaches in cancer. Biochim Biophys Acta Rev Cancer. 2020;1874(1):188394.PubMedCrossRef
102.
103.
Boonstra PA, et al. Clinical utility of circulating tumor DNA as a response and follow-up marker in cancer therapy. Cancer Metastasis Rev. 2020;39(3):999–1013.PubMedPubMedCentralCrossRef
104.
105.
106.
107.
108.
Barua I, et al. Artificial intelligence for polyp detection during colonoscopy: a systematic review and meta-analysis. Endoscopy. 2021;53(3):277–84.PubMedCrossRef
109.
Norton J, et al. Pancreatic cancer associated fibroblasts (CAF): under-explored target for pancreatic cancer treatment. Cancers (Basel). 2020;12(5):1347.CrossRef
110.
Leask A. A centralized communication network: recent insights into the role of the cancer associated fibroblast in the development of drug resistance in tumors. Semin Cell Dev Biol. 2020;101:111–4.PubMedCrossRef
Metadata
Title
Cancer-associated fibroblasts in colorectal cancer
Authors
S. Kamali Zonouzi
P. S. Pezeshki
S. Razi
N. Rezaei
Publication date
01-05-2022
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 5/2022
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-021-02734-2

Other articles of this Issue 5/2022

Clinical and Translational Oncology 5/2022 Go to the issue

Research Article

Tumor microenvironment and its clinicopathological and prognostic associations in surgically resected cutaneous angiosarcoma

Research Article

Analysis of related factors of cervical intraepithelial neoplasia complicated with vaginal intraepithelial neoplasia

Research Article

Long non-coding RNA PVT1 facilitates cell migration and invasion by regulating miR-148a-3p and ROCK1 in breast cancer

Research Article

Resveratrol enhanced chemosensitivity by reversing macrophage polarization in breast cancer

Research Article

Intraoperative irradiation in breast cancer: preliminary results in 80 patients as partial breast irradiation or anticipated boost prior to hypo-fractionated whole breast irradiation

Review Article

Bacterial driver–passenger model in biofilms: a new mechanism in the development of colorectal cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits